How do you pay?

How to pay the least

Ask for the cash price

Leqvio

We didn’t find one.

  1. Ask your pharmacy for Leqvio’s cash price, and one or two other pharmacies too.
  2. Leqvio’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify 

Compare every option

Question
Brand nameLeqvio
Authorized genericinclisiran
Regular genericinclisiran
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Leqvio?
The original
–
–

Brand nameThe maker’s card

LEQVIO Co-pay Program

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on start.leqvio.com 

Or call 1-833-537-8462. See the offer on leqvio.com

In the maker’s words

“If you have private (commercial) insurance, you may be eligible for the LEQVIO Co-pay Program and may pay as little as $0.”

From the maker’s offer on leqvio.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Leqvio itself, from the same company, sold without the brand name, and usually for less. For now Leqvio is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:

  • adults with hypercholesterolemia.
  • adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH).
  • pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy.

Source: the FDA label for Leqvio (Novartis Pharmaceuticals Corporation), August 19, 2026. Full label on DailyMed 

Good to know